세계의 정형외과 임플란트용 황색포도상구균 감염증 진단 및 치료 시장 : 진단 및 치료, 최종사용자, 지역별 예측(-2032년)

Global Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market Research Report Information by Diagnosis & Treatment {(Diagnosis [Microbiological Culture Test, Polymerase Chain Reaction, and Imaging Studies {Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasonography}], Treatment(Antibiotics, Antimicrobial Therapy, and Surgery)}, by End User (Hospitals, Ambulatory Surgery Centers, and Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Market Overview

Staphylococcus aureus Infection Diagnosis and Treatment for Orthopedic Implants The market was valued at USD 2.31 billion in 2022. The staphylococcus aureus infection diagnostics and treatment for orthopedic implants market is expected to increase from USD 2.40 billion in 2023 to USD 3.87 billion by 2032, with a compound yearly growth rate (CAGR) of 4.89% over the forecast period. The increasing number of orthopedic procedures involving implants, as well as the increased incidence of fractures, are driving market expansion.

The growing number of orthopedic procedures is driving up the demand for staphylococcus aureus infection diagnosis and treatment for orthopedic implants. For example, in July 2023, Cleveland Clinic (US) announced that approximately 800,000 knee replacements are performed annually in the United States. Furthermore, the American Association of Hip and Knee Surgeons identifies prosthetic joint infection (PJI) as a serious concern following total hip arthroplasty (THA), particularly when other health issues are present, which increases the risk. The rate of infections caused by staphylococcus aureus increased from 26.3% in 2008-2009 to 40% between 2020 and 2021.

Market Segment insights

The Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market is classified by diagnosis and treatment, with diagnosis further subdivided into microbiological culture test, polymerase chain reaction, and imaging studies.

The Staphylococcus aureus Infection Diagnosis and Treatment for Orthopedic Implant Market is segmented by end user, which includes hospitals, ambulatory surgical centers, and others.

Regional insights

The report divides the market into five regions: the United States, Europe, China, the Middle East and North Africa, and the rest of the world. In 2022, the North American staphylococcus aureus infection diagnostic and treatment for orthopedic implants market held the greatest market share. This is related to the increased prevalence of staphylococcus aureus infection in orthopedic implants, excellent healthcare infrastructure, and an increase in the number of orthopedic procedures in North America.

The Europe staphylococcus aureus infection detection and treatment for orthopedic implants market has the second-largest market share due to an increasing elderly population and favorable reimbursement policies across the country. Furthermore, Germany has the largest market share for staphylococcus aureus infection diagnosis and treatment for orthopedic implants, while the UK is expected to be the fastest-growing market in the European region.

The Asia-Pacific staphylococcus aureus infection diagnostic and treatment market for orthopedic implants is predicted to develop significantly between 2023 and 2032. This is attributable to strong population increase, government initiatives and investments, and coordination among regional healthcare partners.

The rest of the world is divided into three regions: the Middle East, Africa, and Latin America. The staphylococcus aureus infection diagnosis and treatment for orthopedic implants market in the regions is expected to increase as a result of continuing research & development activities to create novel diagnostic technologies, medicines, and preventive methods.

Major Players

Xellia Pharmaceuticals (Germany), Wellona Pharma (India), Schwitz Biotech (India), Merck KGaA (Germany), Thermo Fisher Scientific Inc (US), BioMerieux SA (France), Siemens Healthineers AG (Germany), Beckman Coulter Inc (US), Hoffmann-La Roche Ltd (Switzerland), and Pfizer Inc (US) are among the key companies in the Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research data flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research DATA FLOW:
  • 3.5.2 Primary Research: Number of Interviews conducted
  • 3.5.3 Primary Research: Regional Coverage
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Technique
• 3.8 DATA MODELING
  • 3.8.1 microeconomic factor analysis:
  • 3.8.2 Data modeling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 Growing number of Orthopedic surgeries associated with implants
  • 4.2.2 Increasing incidence of fractures
• 4.3 RESTRAINTS
  • 4.3.1 Stringent regulatory requirements and lengthy approval processes
• 4.4 OPPORTUNITY
  • 4.4.1 Technological treatment for orthopedic associated staphylococcus aureus infection
  • 4.4.2 Growing awareness of early diagnosis and the development of early diagnosis products

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 Threat of New Entrants
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 Threat of Substitutes
  • 5.1.4 Bargaining Power of Buyers
  • 5.1.5 Intensity of Rivalry
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET
• 5.3 QUALITATIVE OVERVIEW ON TREATMENT MANAGEMENT FOR STAPHYLOCOCCUS AUREUS BEFORE CULTURE AND ITS IMPACT ON HEALTHCARE COST
• 5.4 INDICATIVE SHARE (%) FOR IMPLANTS AFFECTED BY STAPHYLOCOCCUS AUREUS BY REGION, (2022)
• 5.5 TOTAL NUMBER OF JOINT REPLACEMENTS AND COMPLICATED FRACTURES REPAIRED WITH PLATES AND SCREWS
• 5.6 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED.
• 5.7 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED WITH STAPHYLOCOCCUS AUREUS (SA) INFECTION
• 5.8 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS REVISED SURGERIES ARE DONE BASED ON AN SA INFECTION
• 5.9 TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES AND TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES INFECTED WITH SA

6 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT

• 6.1 OVERVIEW
• 6.2 DIAGNOSIS
  • 6.2.1 Microbiological Culture Test
  • 6.2.2 Polymerase Chain Reaction
  • 6.2.3 Imaging Studies
    • 6.2.3.1 Computed Tomography (CT)
    • 6.2.3.2 Magnetic Resonance Imaging (MRI)
    • 6.2.3.3 Ultrasonography
• 6.3 TREATMENT
  • 6.3.1 Antibiotics
  • 6.3.2 Antimicrobial Therapy
  • 6.3.3 Surgery

7 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER

• 7.1 OVERVIEW
• 7.2 HOSPITALS
• 7.3 AMBULATORY SURGERY CENTERS
• 7.4 OTHERS

8 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY REGION

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 us
  • 8.2.2 canada
• 8.3 EUROPE
  • 8.3.1 germany
  • 8.3.2 France
  • 8.3.3 UK
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 ASIA-PACIFIC
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 South Korea
  • 8.4.5 australia
  • 8.4.6 Rest of Asia-Pacific
• 8.5 REST OF THE WORLD
  • 8.5.1 Middle East & Africa
  • 8.5.2 Latin America

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 MARKET SHARE ANALYSIS,
• 9.3 COMPETITOR DASHBOARD
• 9.4 PUBLIC PLAYERS STOCK SUMMARY
• 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 Product approval

10 COMPANY PROFILES

• 10.1 XELLIA PHARMACEUTICALS
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 KEY STRATEGIES
• 10.2 WELLONA PHARMA
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 KEY STRATEGIES
• 10.3 SCHWITZ BIOTECH
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 MERCK KGAA
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 Products OFFERed
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 SWOT ANALYSIS
  • 10.4.6 KEY STRATEGIES
• 10.5 THERMO FISHER SCIENTIFIC INC
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 products OFFERed
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 SWOT ANALYSIS
  • 10.5.6 Key Strategy
• 10.6 BIOMERIEUX SA
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 products OFFERed
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 Key Strategy
• 10.7 SIEMENS HEALTHINEERS AG
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 products OFFERed
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 Key Strategy
• 10.8 BECKMAN COULTER INC
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 F. HOFFMANN-LA ROCHE LTD
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 SWOT ANALYSIS
  • 10.9.6 KEY STRATEGIES
• 10.10 PFIZER INC
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 productS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 SWOT ANALYSIS
  • 10.10.6 KEY STRATEGIES

11 DATA CITATIONS